(Q33957168)

30 July 2017

title

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial (English)

1 reference

30 July 2017

0 references

Michael W Konstan

1

1 reference

30 July 2017

David E Geller

2

1 reference

30 July 2017

Predrag Minić

3

1 reference

30 July 2017

Florian Brockhaus

4

1 reference

30 July 2017

Jie Zhang

5

1 reference

30 July 2017

Gerhild Angyalosi

6

1 reference

30 July 2017

publication date

20 October 2010

1 reference

30 July 2017

published in

Pediatric Pulmonology

1 reference

30 July 2017

volume

46

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

230-238

1 reference

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Adherence to the medical regimen: clinical implications of new findings

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Bugs, biofilms, and resistance in cystic fibrosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Standardization of Spirometry, 1994 Update. American Thoracic Society

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Changes in the normal maximal expiratory flow-volume curve with growth and aging

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

5 July 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21356

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21356

Shifting patterns of inhaled antibiotic use in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21356

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21356

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPPUL.21356

Nebulised anti-pseudomonal antibiotics for cystic fibrosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4112574

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20963831

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20963831

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PPUL.21356

1 reference

30 July 2017

1 reference

30 July 2017

1 reference